Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congressdescribe mechanistic insights for greater potency with verekitug compared to ...

– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to ...

Upstream Bio presents data suggesting verekitug offers greater potency than tezepelumab in targeting inflammatory diseases.

About Verekitug Verekitug is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the TSLP receptor and inhibits proinflammatory signaling initiated by ...